- Home
- About mondoBIOTECH
- Investors
- Corporate Fact Sheet
- Company Presentation
- All Reports
- Corporate Governance
- Share Information
- Financial Calendar
- Shareholders’ Meeting
- Investor Relation Contact
- Media Releases
- Business Partners
- Pipeline
- Community
- Careers
- Contact Us
Search
| Investors - Media Releases | ||
| Stay Informed | ||
|
2006
| ||
| December 21, 2006 |
| Prof. Sami I. Said appointed Distinguished Professor by the State University of New York |
| Basel, December 21 2006 - mondoBIOTECH today announces the appointment of Dr. Sami I. Said as Distinguished Professor by the State University of New York for his seminal work on Vasoactive Intestinal Peptide (VIP; Aviptadil). |
| October 23, 2006 |
| mondoBIOTECH Chief Business Architect Fabio Cavalli Swiss Entrepreneur of the Year 2006 |
| mondoBIOTECH's Chief Business Architect Fabio Cavalli winner of the prize Swiss Entrepreneur of the Year 2006 Basel, October 20, 2006 - mondoBIOTECH Chief Business Architect and CEO Fabio Cavalli has been awarded today the Swiss Entrepreneur of the Year 2006 prize for the category "Start up". The Prize is organized every year worldwide by Ernst & Young. |
| October 12, 2006 |
| mondoBIOTECH Completes Patient Enrollment and Treatment in the Phase II AVISARCO Trial |
| Basel, Switzerland, October 12, 2006 - mondoBIOTECH AG announced today the completion of patient enrollment and treatment in the AVISARCO trial, a Phase II clinical trial of inhaled Aviptadil in patients with severe pulmonary sarcoidosis. AVISARCO is an open, uncontrolled clinical Phase II study designed to evaluate the effects of inhaled Aviptadil on the immunologic activity of alveolar macrophages and lymphocytes in patients with severe pulmonary sarcoidosis. |
| September 21, 2006 |
| European Commission grants mondoBIOTECH’s product Aviptadil the Orphan Designation for treating ALI |
| Basel Switzerland, September 21, 2006. mondoBIOTECH AG, a private Swiss biotechnology company, today announced the receipt of an Orphan Medicinal Product Designation (OMPD) by the European Commission for its product Aviptadil for the treatment of Acute Lung Injury (ALI) in the European Union (EU/3/06/395), after the positive opinion given by the European Medicinal Agency (EMEA). |
| September 14, 2006 |
| Biogen Idec and mondoBIOTECH sign collaboration and licensing agreement for Aviptadil in PAH |
| Cambridge, MA and Basel, Switzerland (September 14, 2006) - Biogen Idec (NASDAQ: BIIB) and mondoBIOTECH AG, a private Swiss biotechnology company, today announced the signing of an exclusive collaboration and license agreement for Biogen Idec to develop, manufacture and commercialize Aviptadil, a clinical compound for the treatment of Pulmonary Arterial Hypertension (PAH). |
| July 03, 2006 |
| mondoBIOTECH and Nebu-Tec sign a collaborative agreement for inhalative treatments |
| mondoBIOTECH AG and Nebu-Tec GmbH today announced a collaboration agreement for development and patient support of mondoBIOTECH´s products aiming to treat fatal and rare lung diseases. The first product that is jointly developed is inhaled Aviptadil for Pulmonary Arterial Hypertension. |
| April 28, 2006 |
| mondoBIOTECH signs business alliance with Quintiles to conduct multiple clinical trials |
| Basel, April 28, 2006 - mondoBIOTECH Group today announced a new business alliance with Quintiles, the world's leading pharmaceutical services organization, for clinical study management of trials emerging from mondoBIOTECH's product pipeline. Under the terms of the agreement, Quintiles will provide mondoBIOTECH with full clinical trial services in support of the pivotal Phase 3 trial for mondoBIOTECH's Aviptadil in pulmonary arterial hypertension, as well as for six additional clinical Phase 2 Proof on Concept studies in other indications. |
| March 21, 2006 |
| mondoBIOTECH and BACHEM sign agreement for new projects from screening Bachem Peptide Library |
| mondoBIOTECH and Bachem sign collaboration agreement for the development of new projects deriving from the Bachem Peptide Library Basel and Bubendorf, Switzerland, March 21, 2006 - mondoBIOTECH AG and Bachem AG today announced a new collaboration agreement for the development of new peptide projects for potential therapeutic use in different medical indication areas. Under the terms of the agreement, Bachem grants mondoBIOTECH exclusive general access to its Peptide Library for screening and selecting suitable compounds for the development of new medications. In return, Bachem has the right to produce any peptides selected as potential drug candidates for development and, if approved as pharmaceuticals, the API of the drug. |
